Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock’s move wasn’t …
Why is Arcellx stock up 80% today? Gilead’s $7.8B answer
view original post